Mergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry - Implications and Outlook - 2021 Edition
Summary This report is the third edition of our analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.
New York, July 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Mergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry - Implications and Outlook - 2021 Edition" - https://www.reportlinker.com/p06103613/?utm_source=GNW
Scope
This 55-page report gives important, expert insight you won’t find in any other source. 28 tables and figures throughout the report illustrate major points and trends.
This report is required reading for -
- CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
- Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking
Reasons to Buy
- Overview of M&A in the Pharma CMO Industry
- Detailed view of CDMO performance by number of deals completed from Deals database
- Analysis of the M&A of specific manufacturing services
Read the full report: https://www.reportlinker.com/p06103613/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001